Cogent Biosciences (COGT) Operating Expenses (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Operating Expenses data on file, last reported at $103.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 38.27% year-over-year to $103.6 million in Q1 2026; TTM through Mar 2026 was $362.0 million, a 25.5% increase from a year earlier, with the FY2025 full-year figure at $333.4 million, up 20.81% from the prior year.
• Operating Expenses for Q1 2026 stood at $103.6 million, up from $99.5 million in the prior quarter.
• Over the last five years, Operating Expenses for COGT reached as high as $103.6 million in Q1 2026 and fell as low as $31.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $62.9 million across 5 years, with a median of $62.4 million in 2024.
• Across the five-year window, Operating Expenses surged 145.45% in 2022 and advanced 10.53% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $43.7 million in 2022, then surged by 33.11% to $58.2 million in 2023, then advanced by 26.63% to $73.7 million in 2024, then jumped by 34.94% to $99.5 million in 2025, then increased by 4.13% to $103.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $103.6 million in Q1 2026, $99.5 million in Q4 2025, and $83.4 million in Q3 2025.